Clinical trials: Renal Cell Cancer Metastatic
Urothelial Carcinoma, Bladder Cancer
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
This study aims to analyse the tolerability (side effects and safety) with standard treatment (Javlor®) with the addition of a second anti-tumour drug: sorafenib (Nexavar®).
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- VINSOR (NCT01844947)
- Testing
- Vinflunine, Sorafenib
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 22 people
- Sponsor
- Dr Anders Ullén
Renal Cell Carcinoma
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
This will be a single arm, multi-site phase Ib/II clinical trial of standard doses of High Dose Interleukin-2 (HD IL2) (600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart) in IL-2 eligible clear cell metastatic…
- Trial name
- NCT02989714
- Testing
- Interleukin-2, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan Rogel Cancer Center
Renal Cell Cancer
Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
While different lines of evidence support the notion that renal cell cancer is amenable for immunologic vaccination, up to now the clinical benefit associated with vaccines has been limited.
- Trial name
- rcc (NCT00890110)
- Testing
- Autologous renal cell vaccine based on DNP modified cells
- Volunteers
- 13 people
- Sponsor
- Hadassah Medical Organization
Renal Cell Cancer Metastatic
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety of CM082 in combination with everolimus in Chinese patients with advanced renal cell carcinoma.
- Trial name
- NCT03095040
- Testing
- CM082 combined with everolimus, CM082, Everolimus
- Where
- China
- Volunteers
- 390 people
- Sponsor
- AnewPharma
Kidney Cancer
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.
- Trial name
- NCT00900042
- Testing
- DNA ploidy analysis, DNA stability analysis, chromosomal translocation analysis
- Volunteers
- 34 people
- Sponsor
- SWOG Cancer Research Network
Kidney Cancer Metastatic, Kidney Cancer
SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
This is a multi-institution, single-arm phase II study to determine the safety and efficacy of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of nivolumab and ipilimumab in patients with…
- Conditions
- Kidney Cancer Metastatic, Kidney Cancer, Kidney Cancer, Stage IV
- Trial name
- RADVAX (NCT03065179)
- Testing
- Nivolumab/Ipilimumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00126659
- Testing
- therapeutic conventional surgery, sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab…
- Trial name
- NCT03075423
- Testing
- Ipilimumab plus nivolumab, Standard Therapy
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 316 people
- Sponsor
- Goethe University
Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Optimizing Pazopanib Exposure in RCC Patients
Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.
- Trial name
- OPERA (NCT02089802)
- Testing
- Pazopanib
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Kidney Cancer
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00311545
- Testing
- CNTO 328
- Sponsor
- SWOG Cancer Research Network
Renal Cell Carcinoma, First-line Treatment
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
This is a Phase II, open-label trial to evaluate the efficacy and safety of AK104 monotherapy or AK104 in combination with axitinib as a first-line treatment for advanced/metastatic renal cell carcinoma (RCC).
- Trial name
- NCT05256472
- Testing
- AK104, axitinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease.
- Trial name
- NCT05745142
- Testing
- Sunitinib
- Where
- Turkey (Türkiye)
- Volunteers
- 376 people
- Sponsor
- Pfizer
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Renal Cell Carcinoma, Metastatic Kidney Cancer
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
Patients will undergo a screening process as per standard of care to identify disease type and severity. Careful history and physical examination will also take place to rule out major heart, lung, or kidney disease and pregnancy…
- Trial name
- NCT03189186
- Testing
- Pembrolizumab Injection [Keytruda], Cryoablation, Nephrectomy
- Where
- United States
- Sponsor
- University of California, Irvine
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Metastatic Renal Cell Carcinoma
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
This is a phase I/II open-label study designed to evaluate the combination of pembrolizumab and cabozantinib in subjects with locally advanced, recurrent, or metastatic renal cell carcinoma.
- Trial name
- NCT03149822
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
This randomized clinical trial studies radiation therapy and MK-3475 in treating patients with head and neck cancer, kidney cancer, melanoma, or lung cancer that has returned, has spread to other parts of the body, or cannot be…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma
- Trial name
- NCT02318771
- Testing
- Radiation Therapy (RT), MK-3475
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Oligometastatic Renal Cell Carcinoma
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
This is a phase II trial aiming at assessing the efficacy of pembrolizumab to delay tumor progression in patients with oligometastatic clear cell metastatic Renal Cell Carcinoma (mRCC).
- Trial name
- PE-PE (NCT05578664)
- Testing
- Pembrolizumab injection plus metastasis directed treatment (surgery or RT), Tumor resection or RT
- Where
- 33 sites in Italy
- Volunteers
- 85 people
- Sponsor
- Consorzio Oncotech
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.